Zobrazeno 1 - 10
of 68
pro vyhledávání: ''
Publikováno v:
BMC Cancer
BMC Cancer, Vol 8, Iss 1, p 153 (2008)
BMC Cancer, Vol 8, Iss 1, p 153 (2008)
Background A number of protein markers have been investigated as prognostic adjuncts in breast cancer but their translation into clinical practice has been impeded by a lack of appropriate validation. Recently, we showed that BCL2 protein expression
Autor:
Yalai Bai, William M. Sikov, David L. Rimm, Maysa M. Abu-Khalaf, Lyndsay Harris, Veerle Bossuyt, Huan Cheng, Natalie Sinclair
Publikováno v:
BMC Cancer
Background Preoperative therapy with chemotherapy and the HER2-targeted monoclonal antibody trastuzumab is valuable for patients with large or locally advanced HER2-positive (HER2+) breast cancers but traditional methods of measuring HER2 expression
Autor:
Taher Al-Tweigeri, Ayodele Alaiya, Abdelilah Aboussekhra, Nujoud Al-Yousef, Suad M. Bin Amer, Nisreen Al-Moghrabi, Safia Madkhali, Asma Tulbah, Asmaa Nofel, Zakia Shinwari, Bedri Karakas
Publikováno v:
BMC Cancer
Background BRCA1 promoter methylation has been detected in DNA from peripheral blood cells of both breast cancer patients and cancer-free females. However, the pathological significance of this epigenetic change in white blood cells (WBC) remains an
Autor:
Yoko Nakasu, Koichi Mitsuya, Nakamasa Hayashi, Junichiro Watanabe, Hideyuki Harada, Ichiro Ito
Publikováno v:
BMC Cancer
Background Multiple new targeted agents have been developed for patients with human epidermal growth factor receptor type 2 (HER2) – positive breast cancer. Patients with HER2– positive breast cancer will develop brain metastases with greater inc
Autor:
Claire Josse, Vincent Bours, Pierre Frères, Guy Jerusalem, Bouchra Boujemla, Stephane Wenric, Karin Segers, Raphaël Marée, Joëlle Collignon, Meriem Boukerroucha, Sonia ElGuendi
Publikováno v:
BMC Cancer
Background The BRCA1 gene plays a key role in triple negative breast cancers (TNBCs), in which its expression can be lost by multiple mechanisms: germinal mutation followed by deletion of the second allele; negative regulation by promoter methylation
Publikováno v:
BMC Cancer
BMC Cancer, Vol 12, Iss 1, p 257 (2012)
BMC Cancer, Vol 12, Iss 1, p 257 (2012)
Background Sulfotransferase 1A1 (SULT1A1) participates in the elimination of 4-hydroxy-tamoxifen (4-OH-TAM), which is one of the major active metabolites of tamoxifen (TAM). Homozygous SULT1A1 variant allele genotype has been associated with lower ca
Publikováno v:
BMC Cancer
Background Monoclonal antibodies have been used to effectively treat various tumors. We previously established a unique strategy to identify tumor specific antibodies by capturing B-cell response against breast tumor antigens from patient-derived sen
Autor:
Adrienne Morey, Diana J. Hastrich, David Ingram, Peter C. Willsher, Arlene Chan, Belinda Brown
Publikováno v:
BMC Cancer, Vol 12, Iss 1, p 555 (2012)
BMC Cancer
BMC Cancer
Background Overall survival of HER2 positive metastatic breast cancer patients has been significantly improved with inclusion of trastuzumab to chemotherapy. Several studies have demonstrated discordant HER2 status in the primary and metastatic tumou
Autor:
Birgitte Bruun Rasmussen, Anne Katrine Duun-Henriksen, Sarah Larsen, Anne Vibeke Lænkholm, Christina Westmose Yde, Martin Bak, Anne E. Lykkesfeldt, Tove Kirkegaard
Publikováno v:
Larsen, S L, Yde, C W, Laenkholm, A-V, Rasmussen, B B, Duun-Henriksen, A K, Bak, M, Lykkesfeldt, A E & Kirkegaard, T 2015, ' Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer ', B M C Cancer, vol. 15, 239 . https://doi.org/10.1186/s12885-015-1210-4
BMC Cancer
BMC Cancer
BACKGROUND: Resistance to antiestrogen therapy is a major clinical challenge in the treatment of estrogen receptor α (ER)-positive breast cancer. The aim of the study was to explore the growth promoting pathways of antiestrogen resistant breast canc
Autor:
Michela Tebaldi, Valentina Zampiga, Dino Amadori, Wainer Zoli, Fabio Falcini, Gianluca Tedaldi, Rita Danesi, Daniele Calistri, Lucia Bedei
Publikováno v:
BMC Cancer
Background CHEK2 is a multi-cancer susceptibility gene whose common germline mutations are known to contribute to the risk of developing breast and prostate cancer. Case presentation Here, we describe an Italian family with a high number of cases of